A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
HER2 Positive Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 70 (final count)
- Started
- Dec 1, 2020
- Main results expected
- Jul 15, 2024
- Fully finished
- Mar 7, 2025
- Results posted
- Jul 31, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment
Measured over: From the first dose of study treatment until the first documented PD or before start of any new anti-cancer therapy (up to 43 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04539938 · record last updated 2026-03-23 · checked 2026-11-09 15:36 UTC